非小细胞肺癌患者EGFR基因突变类型与EGFR-TKIs治疗敏感性及疗效关系的研究进展被引量：5

下载PDF

导出

摘要非小细胞肺癌(NSCLC)是常见的肺癌类型.表皮生长因子受体(EGFR)是肺癌最重要的驱动基因之一,EGFR基因突变更易发生在在亚洲女性、不吸烟及病理类型为腺癌的NSCLC患者中.表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)是目前临床常用的NSCLC治疗药物.NSCLC患者接受EGFR-TKIs的疗效与EGFR基因突变类型密切相关.与存在EGFR基因21外显子L858R点突变的NSCLC患者比较,存在EGFR基因19外显子缺失的NSCLC患者对EGFR-TKIs治疗的敏感性高、治疗效果好,无病进展生存期长.

作者蒋琴俞婷婷单莉

机构地区新疆医科大学第三附属医院

出处《山东医药》 CAS 2019年第27期102-105,共4页 Shandong Medical Journal

关键词表皮生长因子受体表皮生长因子受体突变肺癌非小细胞肺癌表皮生长因子受体酪氨酸激酶抑制剂

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献4

1刘仁旺,刘京豪,李昕,李颖,赵青春,李作生,刘红雨,陈军.EGFR 19和21外显子突变肺癌患者的临床特征比较和预后分析[J].中国肺癌杂志,2014,17(11):804-811. 被引量：16
2周彩存,赵印敏,唐亮,高文.非小细胞肺癌组织表皮生长因子受体基因突变的临床意义[J].肿瘤,2005,25(5):458-461. 被引量：10
3李俭杰,曲莉莉,卫星,高红军,王伟霞,秦海峰,汤传昊,郭万峰,王红,刘晓晴.EGFR-TKI一线治疗EGFR基因突变的晚期非小细胞肺癌临床观察[J].中国肺癌杂志,2012,15(5):299-304. 被引量：31
4黄诚,林根,雷源源.EGFR 19 Del的晚期非小细胞肺癌患者一线服用EGFR-TKIs的无进展生存期长于EGFR L858R患者[J].循证医学,2015,15(1):25-28. 被引量：8

二级参考文献50

1Ferlay J, Shin HR, Bray F, et a l. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. IntJ Cancer, 2010, 127(12): 2893-2917.
2Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002, 346(2):92-98.
3Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol, 2005, 23 (11): 2513-2520.
4Cortes-Funes H, Gomez C, Rosell R, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-ceU lung cancer patients. Ann Oncol, 2005, 16(17): 1081-1086.
5Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survial in gefitinib-treated chemorefractorylung adenocarcinomas. Clin Cancer Res,2005, 11 (16): 5878-5885.
6Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8): 735-742.
7Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFIL N Engl J Med, 2010, 362(25): 2380-2388.
8Mok TS, Wu YL, qqaongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N EngIJ Med, 2009, 361(10): 947-957.
9Rafael Rosell, Enric Carcereny, Rad) Gervais, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012,13(3): 239-246.
10Mitsudorni T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plusdocetaxel in patients with non-small-cell lung cancer harbouringmutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010j 11(2): 121-128.